Alumis Inc.

Compare

198 Followers

ALMS Stock Chart & Stats

$4.51

-$0.47(-5.84%)

At close: Jan 08 4:00 PM EST

$4.51

-$0.47(-5.84%)

Day’s Range― - ―

52-Week Range$2.76 - $13.00

Previous CloseN/A

Volume29.29K

Average Volume (3M)629.72K

Market Cap

$469.33M

Enterprise Value-$218.00M

Total Cash (Recent Filing)$486.32M

Total Debt (Recent Filing)$38.78M

Price to Earnings (P/E)―

Beta-2.16

Next Earnings

Nov 12, 2025

EPS Estimate

-0.92

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.77

Shares Outstanding96,879,395

10 Day Avg. Volume537,033

30 Day Avg. Volume629,722

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.46

Enterprise Value/Revenue-9.44

Enterprise Value/Gross Profit-10.50

Enterprise Value/Ebitda0.50

Forecast

1Y Price Target

$19.60

Price Target Upside334.59% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressALMS remains on track to report topline data from the Phase 3 ONWARD program of lead asset envudeucitinib in plaque psoriasis, in line with prior guidance.

Efficacy And Safety ProfileALMS is aiming to demonstrate a profile competitive on efficacy and safety to other Phase 3 advanced oral therapies, with an advantage on convenience, as envu has no food effect and does not require fasting.

Market PositioningManagement’s emphasis on simplicity, lack of prior authorization hurdles, favorable COGS, and a planned QD formulation option bolster its commercial positioning.

Bears Say

Pipeline DelaysPipeline updates include a delay for A-005, now expected to begin a Phase 2 trial in 1H26 vs. 2025 previously.

Alumis Inc. News

Alumis Inc.’s ESK-001 Study: A Potential Game-Changer in Psoriasis Treatment

Alumis Inc. (($ALMS)) announced an update on their ongoing clinical study. Study Overview: Alumis Inc. is conducting a...

1d ago

ALMS

Alumis Inc.’s ESK-001 Study: A Potential Game-Changer for Renal Impairment Treatment

Alumis Inc. (($ALMS)) announced an update on their ongoing clinical study. Study Overview: Alumis Inc. is conducting a...

1d ago

ALMS

Alumis Inc.’s ESK-001 Study: A Potential Game-Changer for Hepatic Impairment Treatment?

Alumis Inc. (($ALMS)) announced an update on their ongoing clinical study. Alumis Inc. is conducting a Phase 1...

1d ago

ALMS

Alumis Inc. Updates Corporate Presentation on Pipeline

Alumis Inc. ( ($ALMS) ) has shared an update. On September 3, 2025, Alumis Inc. updated its corporate...

2M ago

ALMS

Alumis Inc. Reports Q2 2025 Earnings and Strategic Advances

Alumis Inc. ( ($ALMS) ) has released its Q2 earnings. Here is a breakdown of the information Alumis...

2M ago

ALMS

ALMS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Alumis Inc. (ALMS) is scheduled to report 2nd quarter earnings on 08/19/2025. Regarding Q2 estimates, Wall Street analysts...

2M ago

ALMS

Alumis Inc.: Strong Buy Rating Backed by Promising Drug Candidate and Strategic Positioning

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. and keeping the price target...

3M ago

ALMS

Alumis reports Q2 revenue $2.67M, consensus $2.43M

As of June 30, Alumis (ALMS) had cash, cash equivalents and marketable securities of $486.3M. “With patient enrollment...

3M ago

ALMS

Alumis Inc. Concludes 2025 Annual Stockholders Meeting

The latest announcement is out from Alumis Inc. ( ($ALMS) ). On July 30, 2025, Alumis Inc. held...

3M ago

ALMS

Alumis Inc.: Promising Pipeline and Strategic Advancements Justify Buy Rating

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ALMS stock, giving a Buy rating on...

3M ago

ALMS

Alumis initiated with an Overweight at Wells Fargo

Wells Fargo analyst Derek Archila initiated coverage of Alumis (ALMS) with an Overweight rating and $17 price target...

3M ago

ALMS

Alumis Inc.: Buy Rating Affirmed Amid Promising ESK-001 Developments and Strong Financial Projections

Alumis Inc., the Basic Materials sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor...

3M ago

ALMS

Alumis completes patient enrollment in global LUMUS Phase 2b trial of ESK-001

Alumis (ALMS) announced the completion of patient enrollment in its global LUMUS Phase 2b trial of ESK-001, a...

3M ago

ALMS

Alumis promotes Sanam Pangali to chief legal officer

Alumis (ALMS) announced the promotion of Sanam Pangali to chief legal officer and corporate secretary. Sanam most recently...

4M ago

ALMS

ALMS FAQ

What was Alumis Inc.’s price range in the past 12 months?

Alumis Inc. lowest stock price was $2.76 and its highest was $13.00 in the past 12 months.

What is Alumis Inc.’s market cap?

Alumis Inc.’s market cap is $469.33M.

When is Alumis Inc.’s upcoming earnings report date?

Alumis Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 14 days.

How were Alumis Inc.’s earnings last quarter?

Alumis Inc. released its earnings results on Aug 13, 2025. The company reported $0.77 earnings per share for the quarter, missing the consensus estimate of $0.772 by -$0.002.

Is Alumis Inc. overvalued?

According to Wall Street analysts Alumis Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alumis Inc. pay dividends?

Alumis Inc. does not currently pay dividends.

What is Alumis Inc.’s EPS estimate?

Alumis Inc.’s EPS estimate is -0.92.

How many shares outstanding does Alumis Inc. have?

Alumis Inc. has 96,879,395 shares outstanding.

What happened to Alumis Inc.’s price movement after its last earnings report?

Alumis Inc. reported an EPS of $0.77 in its last earnings report, missing expectations of $0.772. Following the earnings report the stock price went down -0.679%.

Which hedge fund is a major shareholder of Alumis Inc.?

Currently, no hedge funds are holding shares in ALMS

Alumis Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-66.35%

Trailing 12-Months

Asset Growth

130.38%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alumis Inc.

Alumis Inc. (ALMS) is a biopharmaceutical company focused on the development and commercialization of therapies for autoimmune and inflammatory diseases. Leveraging cutting-edge scientific research, Alumis aims to address unmet medical needs by advancing its portfolio of innovative treatments. The company operates primarily in the biotechnology and pharmaceuticals sectors, dedicated to improving patient outcomes through targeted therapeutic solutions.

Alumis Inc. (ALMS) Earnings & Revenues

Historic Earnings Reports

ALMS Stock 12 Month Forecast

Average Price Target

$19.60

▲(334.59% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","8":"$8","14":"$14","20":"$20","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8,14,20,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.13,5.735384615384615,7.340769230769231,8.946153846153846,10.551538461538462,12.156923076923078,13.762307692307694,15.367692307692309,16.973076923076924,18.57846153846154,20.183846153846154,21.78923076923077,23.394615384615385,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.13,5.32,6.51,7.7,8.89,10.080000000000002,11.27,12.46,13.650000000000002,14.84,16.03,17.220000000000002,18.41,{"y":19.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.13,4.889230769230769,5.648461538461539,6.407692307692308,7.1669230769230765,7.926153846153847,8.685384615384615,9.444615384615386,10.203846153846154,10.963076923076922,11.722307692307693,12.481538461538463,13.240769230769232,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.69,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.83,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >